PDCD1 and neoplasm: While CTLA-4 inhibitors such as ipilimumab have shown limited efficacy as monotherapy in HNSCC, combination strategies with PD-1/PD-L1 inhibitors are under exploration to enhance T-cell activation both at the tumor site and in draining lymph nodes [11,49,50].